100% accuracy
of data
of data
24/7 scientific
support
support
0% tolerance in
quality of product
quality of product
Stock Locations
- New Jersey, USA
- Czech Republic, EU
- Mumbai, India
* Stock subject to availability.
Documentation
Includes: HPLC, MASS/LC-MS, 1H NMR, FT-IR, Potency, Structure Elucidation Report (SER), and additional analytical data depending on the product.
433289-84-0Atorvastatin EP Impurity A
● In Stock
| Catalogue No.: | VE008745 |
|---|---|
| CAS No.: | 433289-84-0 |
| Mol. Formula: | C33H36N2O5 |
| Mol. Weight: | 540.65 g/mol |
Additional information on CAS 433289-84-0
Parent drug
AtorvastatinIUPAC Name
(3R,5R)-7-[2,3-diphenyl-4-(phenylcarbamoyl)-5-(propan-2-yl)-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acidPharmacopoeial Synonyms
Desfluoro Atorvastatin; Atorvastatin Related Compound AOther Synonyms
(3R,5R)-3,5-Dihydroxy-7-(5-(1-methylethyl)-2,3-diphenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)heptanoic acidSmiles
CC(C)C1=C(C(=C(N1CC[C@H](C[C@H](CC(=O)O)O)O)C2=CC=CC=C2)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4InChI
InChI=1S/C33H36N2O5/c1-22(2)31-30(33(40)34-25-16-10-5-11-17-25)29(23-12-6-3-7-13-23)32(24-14-8-4-9-15-24)35(31)19-18-26(36)20-27(37)21-28(38)39/h3-17,22,26-27,36-37H,18-21H2,1-2H3,(H,34,40)(H,38,39)/t26-,27-/m1/s1Description
Atorvastatin EP Impurity A, also designated Atorvastatin Related Compound A or Desfluoro Atorvastatin (free base), is a structurally defined synthetic-process impurity of the statin scaffold, arising from fluorine deletion at the para-fluorophenyl moiety during upstream synthesis or related side-reaction pathways. It has CAS 433289-84-0, molecular formula C33H36N2O5, and molecular weight 540.65 g/mol. As a non-volatile, lipophilic degradant and process-related impurity, its assignment in pharmacopeial material requires orthogonal characterization by LC-MS/MS, high-resolution MS, and HPLC with UV or diode-array detection, with NMR confirmation where needed. It is considered within impurity profiling frameworks rather than as a genotoxic species.References
“Atorvastatin (Oral Route) Description and Brand Names – Mayo Clinic.†Mayoclinic.org, 2023, www.mayoclinic.org/drugs-supplements/atorvastatin-oral-route/description/drg-20067003. Accessed 15 Apr. 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020702s056lbl.pdf ‌Request a Quote
"*" indicates required fields
Other products related to Atorvastatin impurities
Impurity structure
Parent Drug Name
CAS No.
Name of Impurity
Catalog No.
